Chemical activators of SLC17A2 can engage in various biochemical pathways to upregulate the protein's function. Verapamil, for instance, serves as a calcium channel blocker, leading to an increase in intracellular calcium levels, which is a key activator of SLC17A2, as it promotes the fusion of vesicles, an essential step in the protein's function. Similarly, the tyrosine kinase inhibitor Genistein can enhance SLC17A2 activity by preventing the dephosphorylation of proteins associated with it, thus maintaining SLC17A2 in a more active state. Forskolin, by increasing cAMP levels, indirectly stimulates SLC17A2 through the activation of protein kinase A, which can phosphorylate SLC17A2, thereby increasing its activity. Another agent, Phorbol 12-myristate 13-acetate (PMA), activates protein kinase C, which then phosphorylates SLC17A2, leading to enhanced activity of the protein.
Ionomycin functions by elevating intracellular calcium concentration, triggering calcium-dependent signaling pathways that activate SLC17A2. Monensin, an ionophore, alters intracellular ion concentrations, which in turn can activate SLC17A2 by modifying ion gradients that are crucial for the protein's activity. Brefeldin A disrupts the Golgi apparatus, causing SLC17A2 to redistribute to the plasma membrane where it becomes more active. N6-Cyclopentyladenosine, by stimulating adenosine A1 receptors, can enhance SLC17A2 activity through G protein-coupled receptor signaling pathways. Zinc Pyrithione increases the intracellular concentration of zinc, a metal ion that activates SLC17A2 through specific sensing pathways. Nicotinic Acid, as a precursor to NAD+, participates in redox reactions and energy metabolism that can lead to SLC17A2 activation. Guanfacine, an α2A-adrenergic receptor agonist, activates SLC17A2 through associated G protein-coupled receptor-mediated signaling. Lastly, Bay K 8644, as an L-type calcium channel agonist, directly increases calcium influx, which is a crucial activator of SLC17A2. Each of these chemicals, through their unique mechanisms, can serve to enhance the functional activity of SLC17A2 within cellular processes.
VOIR ÉGALEMENT...
Items 1 to 10 of 12 total
Afficher:
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Le vérapamil, un inhibiteur des canaux calciques, augmente les niveaux de calcium intracellulaire, ce qui active SLC17A2 en favorisant la fusion des vésicules. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
La génistéine, un inhibiteur de tyrosine kinase, renforce l'activité de SLC17A2 en inhibant la déphosphorylation des protéines associées, favorisant ainsi son état actif. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
La forskoline augmente les niveaux d'AMPc, ce qui active la protéine kinase A (PKA), et la PKA phosphoryle la SLC17A2, renforçant ainsi son activité. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
La PMA active la protéine kinase C (PKC) et la phosphorylation médiée par la PKC entraîne l'activation de la SLC17A2. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
L'ionomycine augmente la concentration de calcium intracellulaire, ce qui peut activer SLC17A2 par des voies de signalisation dépendantes du calcium. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
La monensine agit comme un ionophore qui modifie les concentrations d'ions intracellulaires, activant ainsi SLC17A2 en modifiant le gradient ionique. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
La Brefeldine A perturbe la fonction de Golgi, ce qui peut conduire à la redistribution de SLC17A2 vers la membrane plasmique, augmentant ainsi son activité. | ||||||
N6-Cyclopentyladenosine | 41552-82-3 | sc-204117 | 50 mg | $120.00 | 2 | |
Cet agoniste du récepteur de l'adénosine A1 peut renforcer l'activité du SLC17A2 par l'intermédiaire des voies de signalisation des récepteurs couplés à la protéine G. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $47.00 | ||
La pyrithione de zinc peut augmenter la concentration intracellulaire de zinc, qui est connu pour activer SLC17A2 par les voies de détection des ions métalliques. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $61.00 $122.00 | 1 | |
L'acide nicotinique, en agissant comme précurseur du NAD+, peut renforcer l'activité de SLC17A2 par le biais de réactions d'oxydoréduction et du métabolisme énergétique. | ||||||